Trials / Completed
CompletedNCT00042965
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Alliance for Clinical Trials in Oncology · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining capecitabine with gemcitabine in treating patients who have metastatic kidney cancer.
Detailed description
OBJECTIVES: * Determine the objective response rate in patients with metastatic renal cell carcinoma treated with gemcitabine and capecitabine. * Determine the duration of overall and progression-free survival of patients treated with this regimen. * Determine the toxicity of this regimen in these patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | capecitabine | |
| DRUG | gemcitabine hydrochloride |
Timeline
- Start date
- 2002-10-01
- Primary completion
- 2006-09-01
- Completion
- 2006-09-01
- First posted
- 2003-01-27
- Last updated
- 2016-07-14
Locations
50 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00042965. Inclusion in this directory is not an endorsement.